Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Phase I study shows nivolumab is safe and tolerable for relapsed or refractory Hodgkin lymphoma

Philippe Armand • 5 Dec 2014
ASH 2014
Hodgkin Lymphoma Antibodies Checkpoint inhibitors Nivolumab

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Philippe Armand (Dana-Farber Cancer Institute, Boston, MA) discusses the results of a phase I study evaluating the preliminary efficacy and safety of PD-1 inhibitor, nivolumab, in patients with relapsed or refractory classical Hodgkin lymphoma.

More from Philippe Armand

23:35
ASH 2014: Ask the experts Q&A session 1
Catherine Bollard et al. • 6 Dec 2014

Related Videos

2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:50
Results of the EuroNet-PHL-C1 trial: omission of radiotherapy in children and adolescents with cHL
Christine Mauz-Körholz • 8 Dec 2023
1:17
KEYNOTE-667: pembrolizumab plus COPDAC-28 for high-risk cHL with slow early response to OEPA
Christine Mauz-Körholz • 8 Dec 2023
0:52
Managing late effects of treatment in pediatric patients with Hodgkin lymphoma
Christine Mauz-Körholz • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals